lilly zepbound - Search News

News

1st Weight-Loss Pill From Lilly Shows Promising Results

CBS News on MSN · 1d

Eli Lilly says GLP-1 pill for diabetes and weight loss effective in study, plans to seek FDA approval

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

Axios on MSN · 1d

GLP-1 pill: Eli Lilly says its oral orforglipron showing "promising results"

A new oral GLP-1 drug candidate could transform the diabetes and weight loss drug boom. Why it matters: Eli Lilly said on Thursday that its experimental pill — called orforglipron — is showing promising results and could serve as an alternative to blockbuster injectable medications like Ozempic and Mounjaro.

Eli Lilly's new GLP-1 weight loss pill showed success in clinical trial

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, Wegovy, Mounjaro and Zepbound, a clinical trial shows.

1d

Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

7d

Lilly’s Zepbound Keeps Weight Off for Three Years, Study Finds

Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with ...

10dOpinion

Trump-Powered Medicare Setback Adds Bullish Impetus for Eli Lilly & Co (LLY) Stock

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

1don MSN

Where Will Eli Lilly Be in 5 Years?

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

18don MSN

Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.

17don MSN

Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

4don MSN

Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results